• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Precision Cancer Therapies. Volume 2. Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practic

Precision Cancer Therapies. Volume 2. Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practic

9781119824541
945.00 zł
850.50 zł Save 94.50 zł Tax included
Lowest price within 30 days before promotion: 850.50 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies

The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science.

Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).

Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also::

  • Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology
  • Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms
  • Covers FDA-approved drugs and their indications, as well as drugs currently in development
  • Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy
  • Includes boxed sections highlighting major unique points about the information in the chapter

Precision Cancer Therapies, Volume Two:: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.

Product Details
101484
9781119824541

Data sheet

Publication date
2024
Issue number
1
Cover
hard cover
Pages count
496
Dimensions (mm)
224.00 x 283.00
  • List of Contributors xix

    Volume Foreword xxiv

    Volume Preface xxvi

    Series Preface xxviii

    Section I Historical Perspective 1

    1 The Distinguished History of Immunotherapy Development in Cancer 3
    Stephen M. Ansell

    Section II Targeting Cell Surface Receptors 9

    2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11
    George J. Weiner

    3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22
    Jennifer K. Lue and Bruce D. Cheson

    4 Pharmacology to Practice: Targeting CD19 and 22 40
    Nilanjan Ghosh and Sonali M. Smith

    5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52
    Michael Wang

    Section III Antibody Drug Conjugates (ADC) 73

    6 Principles of Antibody Drug Development 75
    Eric L. Sievers

    7 Targeting CD30 in Lymphoid Neoplasms 87
    Barbara Pro

    8 Targeting CD79b in B-cell Malignancies 100
    Colette Owens and Gilles Salles

    9 Radioimmunotherapy: Is There Any Future Role? 108
    Alessandro Broccoli and Pier Luigi Zinzani

    Section IV Targeting Immune Checkpoint 123

    10 The Biology of Immune Checkpoint Blockade 125
    Timothy N. Bullock

    11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 139
    Marc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi

    12 Other Immune Checkpoint Targets of Interest 156
    Clifford M. Csizmar and Stephen M. Ansell

    13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190
    John M. Timmerman

    Section V Targeting Macrophages and SIRP-? – Disrupting the Do Not Eat Me 209

    14 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 211
    Mithunah Krishnamoorthy, Robert A. Uger, and Mark Wong

    15 Single Agent and Rational Combination Experiences with Anti-CD47 Targeted Drugs 225
    Nadia Khan, Swathi Namburi, and Krish Patel

    Section VI EBV Directed Immunotherapies 233

    16 Understanding the Role of EBV Infection in Lymphomagenesis 235
    Hiroshi Kimura and Takayuki Murata

    17 Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies 246
    Jason Yongsheng CHAN, Seok Jin Kim, Soon Thye LIM, Choon Kiat ONG, and Won Seog Kim

    Section VII Exploiting Tumor Associated Antigens with Autologous T-Cells 257

    18 The Scientific Rationale for Targeting Tumor-Associated Antigens 259
    Jean-Sébastien Delisle and Marie-France Aubin

    19 Clinical Experiences with TAA-T in Lymphoid Malignancies 276
    Keri Toner, Hannah Kinoshita, and Catherine M. Bollard

    Section VIII Chimeric Antigen Receptor T-Cells (CAR-T) 289

    20 The Science of CAR-T Cell Technology 291
    Richard C. Godby, Allison M. Bock, Saad S. Kenderian, and Yi Lin

    21 The Spectrum of CAR T Assets in Development: Similarities and Differences 304
    J. Erika Haydu and Jeremy S. Abramson

    22 Clinical Experience with CAR-T Cells for Treatment of B-cell Lymphomas 318
    Stephen J. Schuster and John G. Gribben

    23 Off the Shelf CAR-T/NK Cells 341
    Nancy D. Marin, Alice Zhou, Miriam T. Jacobs, and Todd A. Fehniger

    24 Programming Myeloid Cells with Chimeric Antigen Receptor Myeloid-Based Therapies 360
    Miriam Barnett, Michele Gerber, Siddartha Mukherjee, and Daniel Getts

    Section IX Miscellaneous Topics in Immunotherapy 373

    25 Mechanistic Basis and Role of Immunomodulatory Drugs 375
    John G. Gribben

    26 Analytical Tools to Quantitate Immune Mediated Effects: What Should We Measure and How? 384
    Kevin D. Pavelko and Jose C. Villasboas

    27 The Role of the Microbiome in Immune Response 397
    Máire A. Conrad, Kathleen E. Sullivan, and Judith Kelsen

    28 Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response 406
    Enrica Marchi, Ipsita Pal, John Sanil Manvalan, Kallesh Danappa Jayappa, and Owen A. OConnor

    29 Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma 429
    Bruce D. Cheson

    Conclusions 433

    Must Reads 433

    References 433

    Index 436

You might also like
Comments (0)